Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and NeckGlenn J. Hanna, Robert I. Haddad, Vickie Y. Jo et al.|Clinical Cancer Research|2021Cited by 104
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid CarcinomaKartik Sehgal, Jochen H. Lorch, Θεοδώρα Παππά et al.|JAMA Oncology|2024Cited by 38